Glp-1 Receptor Agonists In Cardiometabolic Syndrome

GLP-1 Receptor Agonists in Cardiometabolic Syndrome

GLP-1 Receptor Agonists: Initial Cardiovascular Evidence

GLP-1 Receptor Agonists and Cardiovascular Benefit

Benefits of SGLT2 Inhibitors and GLP-1 Receptor Agonists

Harvard Medical School Continuing Education

The Role of GLP1 Agonists in Cardiovascular Care, Beyond Weight Loss – A Q&A Session

The Texas Heart Institute

SGLT2 Inhibitors vs GLP-1 Agonists: A Cardiologist and an Endocrinologist Weigh In

Cardiovascular Outcomes With GLP-1 Receptor Agonists in Type 2 Diabetes

Choosing SGLT2 Inhibitors vs GLP-1 Receptor Agonists

Harvard Medical School Continuing Education

I GAINED weight on GLP-1 med Zepbound, at first. Here’s my 13-weeks of weigh-ins weight loss vlog.

Herbivore Lenoir on Zepbound

Zooming in on Cardiovascular Risk Control With Glucagon-Like Peptide-1 Receptor Agonists in Diabetes

The use of GLP-1 receptor agonists for reducing cardiovascular risk on type-2 diabetes patients

Xpeer Medical Education

Exploring the Science and Practice of GLP-1 Receptor Agonists

Professor Lars Ryden - 'Are pleiotropic effects of GLP-1 agonists clinically important?'

At the Limits - Leading Medical Education

Fundamentals of SGLT2i's and GLP-1RA's for CV Risk

American College of Cardiology

Cardiovascular Benefits of GLP-1 RAs

American Heart Association

Roche's head of cardiovascular disease dissects GLP-1 drug trial results

CNBC Television

GLP-1 Agonists in T2D: Cardiovascular Outcomes Data

Could GLP-1 Agonist Have Neurological Benefits?

The Impacts of GLP-1 Agonists on Osteoarthritis and Cardiovascular Disease

Using GLP1 receptor agonists to treat cardiac patients with diabetes

Ted Rogers Centre for Heart Research